uploads///Analysts ratings

Jazz Pharmaceuticals on the Street: Analysts’ Recommendations after 1H17

By

Sep. 7 2017, Published 12:29 p.m. ET

Recent Jazz collaborations

In July 2017, Jazz Pharmaceuticals (JAZZ) entered into a license agreement with XL-Protein GmbH for the rights to develop, manufacture, and market products using XL-Protein’s PASylation technology.

According to the terms of the agreement, Jazz will gain access to XL-Protein’s PASylation technology for the development of asparaginase products intended to extend circulating half-life as well as the duration of therapeutic effect.

Jazz paid XL-Protein $2 million in advance and will pay milestone payments for services and support. Jazz’s collaboration with XL-Protein could be a long-term growth opportunity.

Article continues below advertisement

Analysts’ recommendations

Of the 18 analysts tracking Jazz Pharmaceuticals in September 2017, four suggested a “strong buy,” while eleven suggested a “buy.” Three analysts suggested a “hold,” but none suggested any form of “sell” or “strong sell.”

Around ~83.0% analysts tracking Jazz Pharmaceuticals in September 2017 suggested some form of a “buy” rating.

On September 5, 2017, Jazz Pharmaceuticals had a mean 12-month target price of $182.29, which represents a ~23.53% return on investment. Notably, the Vanguard Mid-Cap Growth ETF (VOT) invests ~0.50% of its total portfolio holdings in Jazz Pharmaceuticals.

Peer ratings

Of the ten analysts tracking Agios Pharmaceuticals (AGIO), three analysts recommended a “strong buy,” while five recommended a “buy.” Two analysts suggested a “hold,” while none suggested any form of a “sell” or “strong sell.”

On September 5, 2017, Agios Pharmaceuticals had a mean 12-month target price of $73.63, which represents a ~19.6% return on investment.

Of the 11 analysts tracking Horizon Pharma (HZNP) in September, three analysts suggested a “strong buy,” while six suggested a “buy.” Two suggested a “hold,” while none suggested any form of “sell” or “strong sell.” On September 5, 2017, Horizon had a mean 12-month target price of $17.00, which represents a ~24.8% return on investment.

Of the 26 analysts tracking Celgene (CELG) in September 2017, 12 suggested a “strong buy,” while ten suggested a “buy.” Three suggested a “hold,” and one suggested a “sell.” On September 5, 2017, Celgene had a mean 12-month target price of $150.17, which represents a ~7.7% return on investment.

Advertisement

More From Market Realist